

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eugenio A. Cefali  
Serial No.: 08/960,557  
Filing Date: October 31, 1997  
For:

Examiner: S.L. Channavajjala  
Group Art Unit No.: 1615  
Confirmation No.: 6174

Methods for Treating Hyperlipidemia With Intermediate Release Nicotinic Acid Compositions  
Having Unique Biopharmaceutical Characteristics

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The following information is submitted pursuant to 37 C.F.R. Section 1.97 and 1.98 in accordance with Applicants' duty of disclosure under 37 C.F.R. Section 1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed. In accordance with 37 C.F.R. Sections 1.97(g)-(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined above by 37 C.F.R. Section 1.56(b) exists.

This Supplemental Information Disclosure Statement is being submitted after the first Office Action on the merits. Authorization is given to charge the \$180.00 fee associated with the filing of this Information Disclosure Statement to deposit account number 04-2223.

**DyKEMA GOSSETT PLLC**  
10 South Wacker Drive, Suite 2300  
Chicago, Illinois 60606 USA  
(312) 876-1700  
(312) 627-2302 (facsimile)  
[www.dykema.com](http://www.dykema.com)  
[ipmail@dykema.com](mailto:ipmail@dykema.com)

Date:

Direct telephone calls to:

Respectfully submitted,

/Lisa V. Mueller/

Attorney for Applicant  
Registration No. 38,978

January 8, 2008

312.627.2184